New Advances Provide Hope for Alzheimer’s Patients

Newswise — Dr. Jeffrey L. Cummings, UNLV research professor and a leading expert on Alzheimer’s disease clinical trials, led a five-year review of all Alzheimer’s drugs in the development pipeline. He says today there is more hope than ever that we’ll one day solve Alzheimer’s. 
 
The paper, “Alzheimer’s disease drug development pipeline: 2020,” was published this week in the journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions.
 
The first time his team published an analysis of experimental drugs in 2014, they quantified a 99 percent failure rate of all therapies in the pipeline. It was the first analysis of its kind and has proven enormously popular with roughly 67,000 downloads and 260 citations. 
 
Currently, there are 121 unique therapies in 136 clinical trials in the pipeline. We recently met with Cummings from the UNLV School…